EPHA2 and urinary bladder carcinoma: Animals bearing three EphA2-positive PDX models of bladder cancer (BL-0293, BL-0382, BL-0440) were treated with four weekly doses of gemcitabine, EphA2-ILs-DTXp, or their combination.